Antithrombotic Treatment for Recurrent Miscarriage

Medicine (United States)

Volumn 94, Issue 45, 2015, Pages e1732-

  Zhang, Tianyi ^a   Ye, Xiaofei ^b   Zhu, Tiantian ^a   Xiao, Xiang ^a   Liu, Yuzhou ^a   Wei, Xin ^a   Leu, Yu ^a   Wu, Cheng ^a   Guan, Rui ^a   Li, Xiao ^a   Guo, Xiaojing ^a   Hu, Huili ^a   He, Jia ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; FIBRINOLYTIC AGENT;

BLEEDING; DRUG SAFETY; FEMALE; HUMAN; LIVE BIRTH; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT MISCARRIAGE; REVIEW; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; THROMBOPHILIA; ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; COMPLICATION; PREGNANCY;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; PREGNANCY;

EID: 84958177994     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001732     Document Type: Review

References (50)

1. Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368:601-611.
2. Rushton DI. Placental pathology in spontaneous miscarriage. Early Pregnancy Loss. London: Springer; 1988:149-157.
3. Rai RS, Regan L, Chitolie A, et al. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol. 1996;103:842-844.
4. Rai RS, Regan L, Clifford K, et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod. 1995;10:2001-2005.
5. Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361:901-908.
6. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril. 2010;93:1234-1243.
7. Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum. 2004;50:1028-1039.
8. Erkan D, Patel S, Nuzzo M, et al. Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. Rheumatology (Oxford). 2008;47 (suppl 3):iii23-iii27.
9. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408-413.
10. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253-257.
11. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12:CR132-CR136.
12. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36:279-287.
13. Tulppala M, Marttunen M, Soderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod. 1997;12:1567-1572.
14. Dolitzky M, Inbal A, Segal Y, et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril. 2006;86:362-366.
15. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362:1586-1596.
16. Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and metaregression. Rheumatology (Oxford). 2010;49:281-288.
17. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115:1256-1262.
18. de Jong PG, Kaandorp S, Di Nisio M, et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev. 2014;7:CD004734.
19. Alalaf S. Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome. Arch Gynecol Obstet. 2012;285:641-647.
20. Schleussner E, Kamin G, Seliger G, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss. Ann Intern Med. 2015;162:485.
21. Pasquier E, de Saint Martin L, Bohec C, et al. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood. 2015;125:2200-2205.
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011: www.cochrane-handbook.org.
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
25. Duval S, Tweedie R. Practical estimates of the effect of publication bias in meta-analysis. Austral Epidemiol. 1998;5:14-17.
26. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124.
27. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101:447-459.
28. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932-944.
29. Tu YK, Needleman I, Chambrone L, et al. A Bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. J Clin Periodontol. 2012;39:303-314.
30. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet. 2009;373:746-758.
31. van der Valk R, Webers CA, Lumley T, et al. A network metaanalysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62:1279-1283.
32. Hartling L, Fernandes RM, Bialy L, et al. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. BMJ. 2011;342:d1714.
33. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment metaanalysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163-171.
34. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e76654.
35. Giancotti A, La Torre R, Spagnuolo A, et al. Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. J Matern Fetal Neonatal Med. 2012;25:1191-1194.
36. Visser J, Ulander VM, Helmerhorst FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost. 2011;105:295-301.
37. Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115:4162-4167.
38. Fawzy M, Shokeir T, El-Tatongy M, et al. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet. 2008;278:33-38.
39. Dendrinos S, Kalogirou I, Makrakis E, et al. Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss. Clin Exp Obstet Gynecol. 2007;34:143-145.
40. Fouda UM, Sayed AM, Abdou AM, et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet. 2011;112:211-215.
41. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000;183:1008-1012.
42. Martinelli I, Ruggenenti P, Cetin I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012;119:3269-3275.
43. Badawy AM, Khiary M, Sherif LS, et al. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol. 2008;28:280-284.
44. Mantha S, Bauer KA, Zwicker JI. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost. 2010;8:263-268.
45. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327:368.
46. Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol. 1993;169:1255-1265.
47. van der Weiden RM, Helmerhorst FM, Keirse MJ. Prostanoid excretion in incipient singleton and twin pregnancies. Am J Obstet Gynecol. 1996;174:1614-1617.
48. van der Weiden RM, Helmerhorst FM, Keirse MJ. Influence of prostaglandins and platelet activating factor on implantation. Hum Reprod. 1991;6:436-442.
49. van der Weiden RM, Wouters JM. Infertility may sometimes be associated with non-steroidal anti-inflammatory drug consumption. Br J Rheumatol. 1997;36:605.
50. Schisterman EF, Silver RM, Lesher LL, et al. Preconception lowdose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet. 2014;384:29-36.